Trial · NCT04428359
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
NCT04428359, Not applicable, Completed, B.P. Koirala Institute of Health Sciences; results first posted 2021-04-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts. Trials, record NCT04428359. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04428359
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
- NCT number
- NCT04428359
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 66 participants, actual
- Lead sponsor
- B.P. Koirala Institute of Health Sciences
- Conditions
- Verruca Viral
- Interventions
- Measles-Mumps-Rubella Vaccine, Vit D
- First posted
- 2020-06-11
- Last updated
- 2021-04-09
- Results first posted
- 2021-04-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Starting of treatment to end of three months follow-up after completing treatment | Percentage of patients showing complete response to IL MMR and IL Vitamin D3 Complete response -Complete disappearance of warts including distant ones and skin texture at the site is restored to normal (100%) Excellent response- Reduction in size and number including distant ones and few residual warts still visible (75-99%) Good response- Some reduction in size only including that of distant ones but no decrease in number of warts (50-74%) Poor or no response- No significant change in size and number of warts (0-49%) |
| Secondary | Number of Participants in Each Education Level Group | At the time of enrollment | Distribution of wart patients into different education level like professional degree, graduate, intermediate, high school, middle school, primary school or illiterate |
| Secondary | Number of Participants in Each Occupation Group | At the time of enrollment | Number of participants with different occupations like professional, semiprofessional, clerical/shop/farm, skilled worker, semiskilled worker, unskilled worker, unemployed |
| Secondary | Duration | At the time of enrollment | Duration of warts |
| Secondary | Effect of the Warts on Patient's Life as Assessed by Dermatological Life Quality Index | At the time of enrollment and at the end of three months follow- up after completion of treatment | Quality of life (QoL) will be measured in wart patients, using the Nepali version of the dermatology life quality index (DLQI) questionnaire before initiation of treatment and at the end of follow up. DLQI contains 10 questions that involves 6 sections: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Questions 1 and 2 assess symptoms and feelings; 3 and 4, daily activities; 5 and 6, leisure; 7, work and school; 8 and 9, personal relationships and 10, treatment. The DLQI consists of 10 questions. Each question is given 4 options from not at all effect (score 0) to very much effect (score 3). The minimum and maximum possible score, thus, is 0 and 30 respectively. Meaning of DLQI Scores 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life . |
| Other | Number of Warts | At the time of enrollment | Number of warts in patients |
| Other | Size | At the time of enrollment | Size range of warts |
| Other | Number of Participants With Each Progression Type | At the time of enrollment | Number of participants with different progressions of warts like Gradual or rapid or stable or regressing lesions |
| Other | Number of Participants Who Had Taken Past Treatment | At the time of enrollment | Frequency of different types of past treatment taken- either traditional or medical treatments |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Starting of treatment to end of three months follow-up after completing treatment | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants in Each Education Level Group | At the time of enrollment | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants in Each Occupation Group | At the time of enrollment | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Duration | At the time of enrollment | months | MEAN | |
| SECONDARY | Effect of the Warts on Patient's Life as Assessed by Dermatological Life Quality Index | At the time of enrollment and at the end of three months follow- up after completion of treatment | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Number of Warts | At the time of enrollment | Warts | MEAN | |
| OTHER_PRE_SPECIFIED | Size | At the time of enrollment | cm | MEAN | |
| OTHER_PRE_SPECIFIED | Number of Participants With Each Progression Type | At the time of enrollment | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Number of Participants Who Had Taken Past Treatment | At the time of enrollment | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Measles, Mumps, Rubella Vaccine | Complete response | 25 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Vitamin D3 | Complete response | 22 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Measles, Mumps, Rubella Vaccine | Excellent response | 2 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Vitamin D3 | Excellent response | 6 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Measles, Mumps, Rubella Vaccine | Good response | 3 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Vitamin D3 | Good response | 1 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Measles, Mumps, Rubella Vaccine | Poor or no response | 1 | Participants | |
| Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts | Vitamin D3 | Poor or no response | 1 | Participants | |
| Number of Participants in Each Education Level Group | Measles, Mumps, Rubella Vaccine | Graduate and higher | 2 | Participants | |
| Number of Participants in Each Education Level Group | Vitamin D3 | Graduate and higher | 4 | Participants |
1 to 10 of 58Source ClinicalTrials.gov
See all 58 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Measles, Mumps, Rubella Vaccine | 33 | |
| Overall Study | STARTED | Vitamin D3 | 33 | |
| Overall Study | COMPLETED | Measles, Mumps, Rubella Vaccine | 31 | |
| Overall Study | COMPLETED | Vitamin D3 | 30 | |
| Overall Study | NOT COMPLETED | Measles, Mumps, Rubella Vaccine | 2 | |
| Overall Study | NOT COMPLETED | Vitamin D3 | 3 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pain | Skin and subcutaneous tissue disorders | Measles, Mumps, Rubella Vaccine | 31 | 31 | 31 |
| other | Pain | Skin and subcutaneous tissue disorders | Vitamin D3 | 30 | 30 | 30 |
| other | Swelling | Skin and subcutaneous tissue disorders | Measles, Mumps, Rubella Vaccine | 0 | 31 | 0 |
| other | Swelling | Skin and subcutaneous tissue disorders | Vitamin D3 | 18 | 30 | 18 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Measles, Mumps, Rubella Vaccine | 1 | 31 | 1 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Vitamin D3 | 5 | 30 | 5 |
| other | Hyperpigmentation | Skin and subcutaneous tissue disorders | Measles, Mumps, Rubella Vaccine | 1 | 31 | 1 |
| other | Hyperpigmentation | Skin and subcutaneous tissue disorders | Vitamin D3 | 9 | 30 | 9 |
| other | Hypopigmentation | Skin and subcutaneous tissue disorders | Measles, Mumps, Rubella Vaccine | 2 | 31 | 2 |
| other | Hypopigmentation | Skin and subcutaneous tissue disorders | Vitamin D3 | 2 | 30 | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Measles, Mumps, Rubella Vaccine | 0 | 31 |
| Total, all-cause mortality | Vitamin D3 | 0 | 30 |
| Total, other adverse events | Measles, Mumps, Rubella Vaccine | 31 | 31 |
| Total, other adverse events | Vitamin D3 | 30 | 30 |
| Total, serious adverse events | Measles, Mumps, Rubella Vaccine | 0 | 31 |
| Total, serious adverse events | Vitamin D3 | 6 | 30 |
Source ClinicalTrials.gov
Papers32
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Measles, Mumps, Rubella Vaccine vs Vitamin D3: deaths from any cause | Trial comparisons |
| Measles, Mumps, Rubella Vaccine vs Vitamin D3: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04428359
GET https://conductscience.org/api/trials/v1/NCT04428359/results?page=2